
AIM Stock Forecast & Price Target
AIM Analyst Ratings
Bulls say
AIM ImmunoTech Inc. has demonstrated a strong positive outlook due to encouraging data from multiple studies, particularly highlighting Ampligen's efficacy in diverse therapeutic areas, including colorectal cancer and post-COVID conditions. The company's recent announcements of positive initial data from its Phase 2a study for colorectal cancer and the Phase 2 study for post-COVID conditions signify potential catalysts for future growth and enhanced investor confidence. The continued progress in research and development of its flagship product, Ampligen, positions AIM ImmunoTech favorably in the market focused on addressing unmet medical needs in cancer and viral diseases.
Bears say
AIM ImmunoTech Inc reported a net loss of $2.8 million, translating to an earnings per share (EPS) of $(3.68), which underperformed against earlier estimates of $(8.00). The company's outlook is hindered by significant risks, including balance sheet and liquidity challenges, potential failures in demonstrating safety and efficacy during clinical trials, and obstacles in securing regulatory approvals. Additional concerns stem from commercialization hurdles, reimbursement issues, competition, and broader macroeconomic factors impacting investor sentiment towards biotech stocks.
This aggregate rating is based on analysts' research of AIM ImmunoTech Inc and is not a guaranteed prediction by Public.com or investment advice.
AIM Analyst Forecast & Price Prediction
Start investing in AIM
Order type
Buy in
Order amount
Est. shares
0 shares